A Phase 2, Randomized, Open-Label, Parallel, Comparative, Dose-Finding Study to Evaluate the Efficacy and Safety of AMG531 in Aplastic Anemia Subjects With Thrombocytopenia Refractory to Immunosuppressive Therapy

Trial Profile

A Phase 2, Randomized, Open-Label, Parallel, Comparative, Dose-Finding Study to Evaluate the Efficacy and Safety of AMG531 in Aplastic Anemia Subjects With Thrombocytopenia Refractory to Immunosuppressive Therapy

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Dec 2017

At a glance

  • Drugs Romiplostim (Primary)
  • Indications Aplastic anaemia
  • Focus Therapeutic Use
  • Sponsors Kyowa Hakko Kirin Korea
  • Most Recent Events

    • 12 Dec 2017 Interim exploratory analysis results (n=10) assessing the influence of RMP after a 2-year treatment period on the hematopoietic stem cells and progenitor cells, and on mesenchymal stromal cells presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
    • 07 Jun 2017 Status changed from recruiting to active, no longer recruiting.
    • 22 Feb 2017 Status changed from active, no longer recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top